| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that Clearmind Medicine Inc. (“Clearmind”) (CSE:CMND), (OTC:CMNDF), (FSE: CWY0), has filed a provisional patent application related to metabolic syndromes including obesity, regarding the Company's collaboration with Clearmind.
The patent application is the third of the collaboration, each referring to the proprietary combination of SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™ (for treating obesity and its related metabolic disorders) and Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions and based on research at the Hebrew University.
"Our collaboration with Clearmind focuses on treating different addictions and binge behaviors, using the benefits of our technology and Clearmind's. Obesity, over- weightness and binge eating are among the biggest health concerns of the past decade and are related to addictive behavior, and yet treating options available in the market are very limited," commented Oz Adler, SciSparc's Chief Executive Officer. "We believe that combining MEAI with SciSparc's CannAmide™ may create a great opportunity in treating these conditions."
